Indogulf Cropsci Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Fertilizers & Agrochemicals | Market Cap: ₹460 Cr
The company aims for strong growth with plans to reach INR 1,500-1,600 crores revenue in the next 2-3 years, supported by expanded manufacturing capacity (INR 1,600-1,800 crores potential from new plant). The company expects steady growth driven by high-margin products, demand generation, and deeper rural penetration via subsidiary AbhiPrakash Globus Pvt Ltd.
From Indogulf Cropsci's Q4 FY26 earnings-call transcript · updated 25 Aug 2026.
Price
₹72
Market Cap
₹460 Cr
P/E Ratio
11.9
How does Indogulf Cropsci rank in Fertilizers & Agrochemicals?
Compare Indogulf Cropsci against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.
Indogulf Cropsci — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹109 Cr, net profit ₹4 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company aims for strong growth with plans to reach INR 1,500-1,600 crores revenue in the next 2-3 years, supported by expanded manufacturing capacity (INR 1,600-1,800 crores potential from new plant).
- →Specialty products are expected to grow, with new launches planned in nutrients, herbicides, and fungicides boosting portfolio differentiation.
- →Biologicals and plant nutrients currently at 11% revenue mix will grow in absolute terms with high margins but are expected to remain around the same percentage.
- →Exports will remain a significant growth driver, with expansion into new markets like Venezuela, Taiwan, and Sri Lanka.
- →The integrated agri-solutions approach and deeper farmer engagement aim to sustain continuous demand across crop cycles.
- →Working capital cycles align with industry standards (~200-220 days), with creditor support and limited debt increase expected as volumes grow.
- →Overall, the company targets a healthy growth trajectory built on product diversification and operational scalability.
📈 Profitability & Margins
- →The company expects steady growth driven by high-margin products, demand generation, and deeper rural penetration via subsidiary AbhiPrakash Globus Pvt Ltd.
- →Biologicals and specialty plant nutrients are anticipated to grow in absolute terms, contributing positively to margins.
- →EBITDA and PAT growth in FY26 outpaced revenue growth, supported by better product mix, operational efficiency, and cost control.
- →The company projects healthy top-line growth around 19-20%, maintaining EBITDA margins of approximately 10-11%, though exact forward-looking figures are not committed.
- →Expansion of manufacturing capacity is expected to support revenue potential up to INR1,600-1,800 crores within 3-4 years.
- →Exports and differentiated products provide additional growth levers.
- →Working capital and debt levels expected to rise moderately in line with volume growth but managed via good creditor discipline and bank facilities.
- →Overall, management aims for a balanced growth trajectory while improving profitability and EPS via product diversification and operational optimization.
🏗️ Capital Expenditure Plans
- →Indogulf Cropsciences is expanding its Barwasni facility capacity by approximately 30%-40%, expected to be operational by the end of FY27.
- →The expansion includes compliance and licensing processes involving the Central Insecticide Board, state authorities, fertilizer licenses, and pollution clearances.
- →Capex till date is around INR 76 crores, with an additional INR 8-10 crores planned.
- →The new plant’s capacity can support revenues up to INR 1,600-1,800 crores, sufficient for the next 3-4 years of expansion.
- →The expansion mainly focuses on warehousing raw materials and finished goods to reduce inventory days and improve on-time inventory preparation.
- →Indogulf intends to invest in automation and process optimization to improve manufacturing efficiency.
- →A strategic focus on backward integration, regulatory capabilities, product development, and innovation pipeline continued.
- →Collaboration with ICAR-IARI under The Prime Minister's Fellowship for Doctoral Research supports research-led agricultural innovations.
💰 Fundraising & Capital Structure
- →Currently, the company does not have major term loans; existing debt primarily consists of working capital and some vehicle loans.
- →Working capital needs will increase with higher volumes, potentially leading to increased working capital loans.
- →Debt-equity ratio has improved from 0.8% to 0.4%, indicating low leverage.
- →Sanjay Aggarwal emphasized reliance on creditors (both domestic and overseas) to support working capital rather than debt.
- →Some working capital support will be utilized from bankers but to a limited extent.
- →Capex of around INR 10 crores is planned for plant expansion with no indication of raising equity for this.
- →Future debt addition could be in the ballpark of INR 70-100 crores if revenue increases by 50% (e.g., INR700 crores to INR1000 crores).
- →No mention of any planned equity fundraising during the discussed period (FY27-FY29).
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Indogulf Cropsci Q4 FY26 results?
The company aims for strong growth with plans to reach INR 1,500-1,600 crores revenue in the next 2-3 years, supported by expanded manufacturing capacity (INR 1,600-1,800 crores potential from new plant). The company expects steady growth driven by high-margin products, demand generation, and deeper rural penetration via subsidiary AbhiPrakash Globus Pvt Ltd.
What is Indogulf Cropsci share price analysis?
Indogulf Cropsci currently shows a neutral. The stock trades at a P/E of 11.9 with a market cap of ₹460 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indogulf Cropsci planning capital expenditure?
Indogulf Cropsciences is expanding its Barwasni facility capacity by approximately 30%-40%, expected to be operational by the end of FY27.
Keep Indogulf Cropsci on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.